Phillip Liu

1.7k total citations
16 papers, 468 citations indexed

About

Phillip Liu is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Phillip Liu has authored 16 papers receiving a total of 468 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Molecular Biology and 5 papers in Immunology. Recurrent topics in Phillip Liu's work include Protein Degradation and Inhibitors (5 papers), Cytokine Signaling Pathways and Interactions (3 papers) and Glycosylation and Glycoproteins Research (2 papers). Phillip Liu is often cited by papers focused on Protein Degradation and Inhibitors (5 papers), Cytokine Signaling Pathways and Interactions (3 papers) and Glycosylation and Glycoproteins Research (2 papers). Phillip Liu collaborates with scholars based in United States, Switzerland and South Africa. Phillip Liu's co-authors include Bruce Ruggeri, Matthew C. Stubbs, Dineo Khabele, Andrew J. Wilson, Natalie D. King, Cheng‐Han Huang, Krishna Niyogi, Eric Soupène, Sydney Kustu and Gregory Hollis and has published in prestigious journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Phillip Liu

14 papers receiving 459 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Phillip Liu United States	9	241	157	113	81	51	16	468
Christine Mione Kiefer United States	12	457 1.9×	125 0.8×	67 0.6×	120 1.5×	45 0.9×	16	618
Vaidehi Krishnan Singapore	12	494 2.0×	114 0.7×	75 0.7×	31 0.4×	99 1.9×	27	637
D K Watson United States	8	344 1.4×	77 0.5×	106 0.9×	36 0.4×	87 1.7×	9	554
Jens Rüschmann Canada	12	301 1.2×	70 0.4×	61 0.5×	60 0.7×	220 4.3×	15	514
Meropi Athanasiou United States	12	450 1.9×	120 0.8×	100 0.9×	56 0.7×	79 1.5×	15	639
Hanako Daino Japan	10	326 1.4×	153 1.0×	59 0.5×	52 0.6×	174 3.4×	11	486
Catherine Dehainault France	14	343 1.4×	295 1.9×	28 0.2×	46 0.6×	27 0.5×	21	637
Jonathan D. Rubin United States	8	254 1.1×	120 0.8×	40 0.4×	111 1.4×	75 1.5×	14	514
Gustav Klobeck Germany	8	221 0.9×	154 1.0×	34 0.3×	91 1.1×	120 2.4×	9	472
Hee-Don Chae South Korea	11	476 2.0×	223 1.4×	82 0.7×	49 0.6×	61 1.2×	13	635

Countries citing papers authored by Phillip Liu

Since Specialization

Citations

This map shows the geographic impact of Phillip Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phillip Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phillip Liu more than expected).

Fields of papers citing papers by Phillip Liu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Phillip Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phillip Liu. The network helps show where Phillip Liu may publish in the future.

Co-authorship network of co-authors of Phillip Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Phillip Liu. A scholar is included among the top collaborators of Phillip Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Phillip Liu. Phillip Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Silberstein, John L., Jasper Du, Kun‐Wei Chan, et al.. (2024). Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function. Proceedings of the National Academy of Sciences. 121(12). e2310866121–e2310866121. 27 indexed citations

Hartmann, Griffin G., et al.. (2023). An engineered interleukin‐11 decoy cytokine inhibits receptor signaling and proliferation in lung adenocarcinoma. Bioengineering & Translational Medicine. 8(6). e10573–e10573. 4 indexed citations

Dey, Joyoti, Phillip Liu, Michele Mayo, et al.. (2021). 603 Targeted STAT3 degradation leads to remodeling of an immunosuppressive tumor microenvironment and subsequent sensitization to immune checkpoint therapy. SHILAP Revista de lepidopterología. A633–A633.

Leal, Ana S., Phillip Liu, Teresa Krieger-Burke, Bruce Ruggeri, & Karen T. Liby. (2020). The Bromodomain Inhibitor, INCB057643, Targets Both Cancer Cells and the Tumor Microenvironment in Two Preclinical Models of Pancreatic Cancer. Cancers. 13(1). 96–96. 18 indexed citations

Rong, Haojing, Kirti Sharma, Bin Yang, et al.. (2020). Mechanisms of the Anti-Tumor Activity of STAT3 Degraders in Lymphoma. Blood. 136(Supplement 1). 42–42.

Wilson, Andrew J., Matthew C. Stubbs, Phillip Liu, Bruce Ruggeri, & Dineo Khabele. (2018). The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer. Gynecologic Oncology. 149(3). 575–584. 88 indexed citations

Lee, Sang‐Hyun, Melody Diamond, Alla Volgina, et al.. (2018). Abstract 3929: The FAD-directed LSD1 specific inhibitor, INCB059872, inhibits cell migration and metastasis by suppressing premetastatic niche formation in a spontaneous metastasis mouse model. Cancer Research. 78(13_Supplement). 3929–3929. 4 indexed citations

Schafer, Johanna M., Brian D. Lehmann, Phillip Liu, et al.. (2017). Abstract 1518: Mechanisms of bromodomain and extra-terminal motif inhibitor (BETi) sensitivity in triple-negative breast cancer (TNBC). Cancer Research. 77(13_Supplement). 1518–1518. 1 indexed citations

Vázquez, Ramiro, Gianluca Civenni, Martina Marchetti‐Deschmann, et al.. (2017). Abstract 5080: BET inhibitors INCB054329 and INCB057643 display significant activity in androgen-independent prostate cancer models. Cancer Research. 77(13_Supplement). 5080–5080. 2 indexed citations

10.

Liu, Xuesong, Matthew C. Stubbs, Min Ye, et al.. (2016). Abstract 4702: Combination of BET inhibitor INCB054329 and LSD1 inhibitor INCB059872 is synergistic for the treatment of AML in vitro and in vivo. Cancer Research. 76(14_Supplement). 4702–4702. 6 indexed citations

11.

Zhang, Qiang, Yan Zhang, Sharon Diamond, et al.. (2014). The Janus Kinase 2 Inhibitor Fedratinib Inhibits Thiamine Uptake: A Putative Mechanism for the Onset of Wernicke’s Encephalopathy. Drug Metabolism and Disposition. 42(10). 1656–1662. 85 indexed citations

12.

Chen, Peter, John K. McGuire, Robert C. Hackman, et al.. (2008). Tissue Inhibitor of Metalloproteinase-1 Moderates Airway Re-Epithelialization by Regulating Matrilysin Activity. American Journal Of Pathology. 172(5). 1256–1270. 48 indexed citations

13.

Fridman, Jordan S., Roberto Nussenzveig, Phillip Liu, et al.. (2007). Discovery and Preclinical Characterization of INCB018424, a Selective JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders.. Blood. 110(11). 3538–3538. 23 indexed citations

14.

Yuan, Chao‐Xing, Richard Wynn, Nicola T. Neff, et al.. (2003). Purification of Her-2 extracellular domain and identification of its cleavage site. Protein Expression and Purification. 29(2). 217–222. 39 indexed citations

15.

Soupène, Eric, Natalie D. King, Phillip Liu, et al.. (2002). Rhesus expression in a green alga is regulated by CO ₂. Proceedings of the National Academy of Sciences. 99(11). 7769–7773. 113 indexed citations

16.

Bystryn, Jean‐Claude, et al.. (1985). Immunophenotype of human melanoma cells in different metastases.. PubMed. 45(11 Pt 2). 5603–7. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact